GLP-1 Receptor Agonists Tied to Fewer Respiratory Flare-Ups in Real-World Data
An observational study using U.K. records found that patients with asthma or COPD who initiated GLP-1 receptor agonists had a 14% lower risk of exacerbations compared to those starting sulfonylureas. Semaglutide showed the strongest association with a 30% reduction, and the effect appeared independent of metabolic factors, suggesting possible direct pulmonary benefits. Researchers caution that these findings require confirmation in clinical trials before altering prescribing practices.
The study analyzed electronic health records from over 1.1 million U.K. adults with asthma or COPD, tracking those newly prescribed GLP-1 drugs versus sulfonylureas. Respiratory flare-ups were defined as requiring steroid bursts, emergency visits, hospital admissions, or death, with the overall risk dropping by 14%.
Among specific agents, semaglutide demonstrated the most pronounced association, cutting exacerbation risk by 30% overall, including 38% among asthma patients and 21% among COPD patients. Crucially, this effect remained consistent irrespective of patients' starting weight, insulin resistance, or changes in glucose control, suggesting the drug class may act through pathways independent of metabolic improvements.
If confirmed by randomized trials, these findings could eventually broaden the clinical utility of GLP-1 receptor agonists beyond diabetes and obesity, offering a new adjunctive strategy for managing chronic airways disease. For the millions living with asthma or COPD, this may translate into fewer severe attacks and reduced hospitalizations. However, until interventional studies validate the causal link, prescribing practices are unlikely to shift, and patients should not seek these drugs solely for respiratory relief. The results may also steer pharmaceutical research toward investigating pulmonary mechanisms of this drug class.